Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects

The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.

Inclusion:

• Between 18 and 60 years old at the Screening Visit;
• Women of childbearing potential must have a negative pregnancy test and must agree to use double-barrier contraception;
• BMI > 18.5 and < 32.0 kg/m2 at the Screening Visit;
• In overall good health with no clinically significant laboratory, ECG, or physical exam findings;
• Other inclusion criteria per protocol.

Exclusion:

• History of any clinically-significant medical condition;
• Other exclusion criteria per protocol.